Coverage dated January 10, 2022 to January 12, 2022
Medicare limits coverage of $28,000-a-year Alzheimer's drug
Headline from 12News Now Beaumont
For Medicare to pay, patients will have to be part of clinical trials to assess Aduhelm’s effectiveness against early-stage dementia and its safety.
12News Now Beaumont's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
The Food and Drug Administration approved the drug in June even though its panel of scientific advisers said there was not enough evidence to show it was effective.
Medicare will cover the controversial Alzheimer's drug Aduhelm only if a patient is enrolled in a clinical trial, the Centers for Medicare and Medicaid Services (CMS) proposed Tuesday.
In a key decision, the Centers for Medicare and Medicaid Services (CMS) said today that Medicare will not pay for the controversial Alzheimer’s drug Adulhelm until it sees positive results from a government-approved trial.
Medicare said Tuesday it will limit coverage of a $28,000-a-year Alzheimer’s drug whose benefits have been widely questioned, a major development in the nation’s tug-of-war over the fair value of new medicines that offer tantalizing possibilities but come with prohibitive prices.
Aduhelm is the first treatment approved in the country to slow cognitive decline in those living with Alzheimer's. Doctors have refused to prescribe it, given the lack of data and evidence behind it.
The Centers for Medicare and Medicaid Services announced Tuesday it plans to cover Aduhelm, a monoclonal antibody treatment for Alzheimer’s disease, only if patients are enrolled in ongoing clinical trials cleared by CMS.
On January 11, Medicare issued a draft memorandum that it will only pay for Aduhelm under the so-called coverage with evidence development (CED) pathway. On one hand, proponents say Medicare can learn whether the drug works in the context of a CED study. On the other, critics say CED impedes access.
TUESDAY, Jan. 11, 2022 (HealthDay News) -- It's a move that could severely limit the number of people taking the controversial new Alzheimer's drug Aduhelm: Medicare on Tuesday proposed to
By Tami Luhby, CNN Medicare has proposed covering the controversial and costly Alzheimer’s drug Aduhelm only for those enrolled in qualifying clinical trials, the Centers for Medicare and Medicaid Services announced Tuesday.
Under a proposal announced Tuesday, Medicare would cover the expensive and controversial Alzheimer's drug Aduhelm — but only for those participating in clinical trials.
WASHINGTON -- Medicare said Tuesday that it will limit coverage of the $28,000-a-year Alzheimer's drug whose benefits have been widely questioned, a major development in the nation's tug-of-war over the fair value of new medicines that offer tantalizing possibilities but come with prohibitive prices…
The Centers for Medicare and Medicaid Services announced that it would only cover the expensive new Alzheimer’s treatment from Biogen for patients enrolled in clinical trials, significantly limiting the patient population that could benefit from it.
The Medicare program’s proposal to severely limit coverage of new Alzheimer’s treatments including Biogen’s Aduhelm threatens to hurt sales of the controversial drug and dim prospects for similar medicines in
The Centers for Medicare and Medicaid Services proposed covering the Alzheimer’s drug called Aduhelm only for Medicare patients enrolled in trials cleared by the agency.
Showing the first 25 of 26 headlines. ·
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
Medicare limits coverage of $28,000-a-year Alzheimer's drug | Since Then
